Articles published by Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

VRRM Investors Have Opportunity to Join Verra Mobility Corporation Fraud Investigation with the Schall Law Firm

Today 17:34 EDT

From The Schall Law Firm

Via Business Wire

PLAB Investors Have Opportunity to Join Photronics, Inc. Fraud Investigation with the Schall Law Firm

Today 17:27 EDT

From The Schall Law Firm

Via Business Wire

CZR Investors Have the Opportunity to Join Investigation of Caesars Entertainment, Inc. with the Schall Law Firm

Today 17:05 EDT

From The Schall Law Firm

Via Business Wire

Berkshire Hathaway to Acquire Taylor Morrison Home Corporation for $8.5 Billion

Today 16:30 EDT

From Berkshire Hathaway Inc.

Via Business Wire

GAP Investors Have Opportunity to Join The Gap, Inc. Fraud Investigation with the Schall Law Firm

Today 16:29 EDT

From The Schall Law Firm

Via Business Wire

Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China

Today 9:06 EDT

From Summit Therapeutics

Via Business Wire

Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug Development

Today 8:30 EDT

From Tempus AI, Inc.

Via Business Wire

Pfizer’s BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer

Today 8:00 EDT

From Pfizer Inc.

Via Business Wire

Kelonia Therapeutics Presents Updated First-in-Human Data from Phase 1 inMMyCAR Study of KLN-1010 in vivo BCMA CAR-T Therapy at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Today 8:00 EDT

From Kelonia Therapeutics, Inc.

Via Business Wire

ASCO 2026: Bayer Shares New Findings for NUBEQA® (darolutamide) Regarding Cognitive Decline in Men with Advanced Prostate Cancer Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial

May 30, 2026

From Bayer

Via Business Wire

Salubris Biotherapeutics Announces Updated Phase 1/2 Data for JK06, a 5T4-Targeted Antibody Drug Conjugate, at the 2026 American Society of Clinical Oncology Annual Meeting

May 30, 2026

From Salubris Biotherapeutics, Inc.

Via Business Wire

BW LPG Enters Into Agreement for Eight 90’cbm Panamax Newbuildings with Hyundai Heavy Industries

May 30, 2026

From BW LPG Limited

Via Business Wire

Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026

May 30, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Sportradar Group AG (SRAD) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

May 30, 2026

From Robbins Geller Rudman & Dowd LLP

Via Business Wire

CVLT INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Commvault Systems, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

May 30, 2026

From Robbins Geller Rudman & Dowd LLP

Via Business Wire

Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026

May 30, 2026

From Exelixis, Inc.

Via Business Wire

Massive Bio Announces Next-Generation Reticulum Nexus™ Product Suite at ASCO 2026

May 30, 2026

From Massive Bio

Via Business Wire

Tempus Launches the PRECISION Challenge, a National Program Opening Its Foundation Model Work to the Broader Research Community

May 30, 2026

From Tempus AI, Inc.

Via Business Wire

Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026

May 30, 2026

From Summit Therapeutics

Via Business Wire

ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer

May 30, 2026

From Veracyte, Inc.

Via Business Wire

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL

May 30, 2026

From Incyte

Via Business Wire

Tempus Introduces ‘Preview’: Bridging the Critical Time Gap Between Diagnostic Order and Definitive Results

May 30, 2026

From Tempus AI, Inc.

Via Business Wire

Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting

May 30, 2026

From Immunome, Inc.

Via Business Wire

TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer

May 30, 2026

From Pfizer Inc.

Via Business Wire

Tune Therapeutics Presents Positive Phase 1b/2a Proof of Concept Data on TUNE-401: a First-in-Class Epigenetic Silencer for Patients with Hepatitis B at EASL 2026

May 30, 2026

From Tune Therapeutics

Via Business Wire

FCPT Announces Agreement to Acquire up to 102 Mission Pet Health Veterinary Properties for $268 Million

May 29, 2026

From Four Corners Property Trust

Via Business Wire

AVAV INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that AeroVironment, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

May 29, 2026

From Robbins Geller Rudman & Dowd LLP

Via Business Wire

Shareholder Notice: Robbins LLP Informs Investors of the Lucid Group, Inc. Class Action

May 29, 2026

From Robbins LLP

Via Business Wire

Ferrari Films Issues Formal Rebuttal to Forbes Article Mischaracterizing Section 168(k) as "Worthless" for Film Investors

May 29, 2026

From Ferrari Films

Via Business Wire

YSS INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving York Space Systems Inc.

May 29, 2026

From Kirby McInerney LLP

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.